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D Abstract - Graft-versus-host disease (GVHD) remains a 
major complication of bone marrow transplantation. This 
report describes reversal of GVHD by infusion of stored re-
cipient bone marrow following combined liver-bone marrow 
allotransplantation. Graft-versus-host disease developed at 
the end of the first postoperative week. The skin involvement 
progressively spread to approximately 800/0 of the body sur-
face and was not affected by modification of the immuno-
suppressive treatment. On the 42nd and 43rd postoperative 
day 1.23 x 108 and 1.6 x 108 autologous bone marrow cells 
per kg of recipient body weight were infused. The skin rush 
began to dramatically improve and resolved within 2 wk from 
the autologous marrow infusion. Autologous bone marrow 
storage previous to allogeneic bone marrow transplantation 
for tolerance induction could constitute a safety net in case 
of occurrence of GVHD. 
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The concept of graft-versus-host disease (GVHD) as 
the recognition of the host by immunologically com-
petent cells of the graft was first delineated by Bil-
lingham and Brent (1), following spleen cell and bone 
marrow transplantation. However, it was soon recog-
nized that the same problem could affect recipients of 
organs that are rich in lymphoid tissue (2-12). In this 
report, we describe reversal of GVHD by infusion of 
stored autologous bone marrow in a recipient of a 
combined liver-bone marrow transplant. 
CASE REPORT 
A 56-yr-old man underwent upper abdominal exen-
teration and liver transplantation on July 16, 1992 for 
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a gastric leiomyosarcoma with liver metastases. Using 
standard techniques autologous bone marrow cells 
were harvested before the surgical procedure and 
stored in liquid nitrogen (14). A few hours before op-
eration, the patient was treated with a single dose of 
550 rads thoraco-abdominal lymphoid irradiation 
(TLI). Bone marrow cells from the same donor as the 
liver allograft were separated from vertebral bodies ob-
tained at the time of the multiorgan donor procedure. 
Then, 2 X 108 bone marrow cells per kg of recipient 
body weight were infused IV through a central line im-
mediately after the orthotopic liver transplant. Post-
operative immunosuppression was with conventional 
doses of FK 506 and prednisone (Fig. 1). 
A skin rash developed at the end of the first post-
operative week that was initially mild and confined to 
the areas exposed to the preoperation irradiation. The 
rash worsened during the second postoperative week, 
and on the 15th postoperative day (POD), the diagno-
sis of GVHD that was Grade 2 by the criteria of Lerner 
et al. (13) was made on a skin biopsy. On days 21 and 
32 progressively more florid changes compatible with 
acute GVHD were seen in second and third skin biop-
sies. The skin biopsy obtained on POD 15 showed a 
mild, predominantly T-Iymphocyte infiltrate localized 
to the upper dermis and associated with focal exocyto-
sis and spongiosis. Occasional keratinocyte necrosis 
was present. Immunoperoxidase studies disclosed that 
the infiltrating cells were of donor HLA type. The sec-
ond biopsy on POD 21 revealed more florid changes 
which included acantholysis and focal cleft formation 
School of Medicine, PO Box 016960 (R-134), Miami, FL 
33101. 
188 Cell Transplantation. Volume 3, Number 2, 1994 
50 
40 
30 
20 
10 
l~----~~~~--~------KKKgi~i---~------~fA-~ 
-...J 
-::J 
I-
(J) 
« 
• 
650 
550 
450 
350 
250 
150 
550 
450 a 
» 
350 , ~ 
250 
150 C 
-
, 
-~l RMi-~~~~~~~~~as~~~~~ __ --t 
c: 4.5 
:g =- 3.5 
:EJ2 
~ ~ 2.5 
n:J -(5 1.5 
l-
• 0.5 
>: 0.8 
n:J 
:g, 0.6 
~ 
0) 0.4 
.s 
<0 0.2 0 
II) 
~ 0 LL 
Q) 50 
c: -0>' K~ ~ 100 
c:--£ .§: 150 
• 200 ~---:-::------=~i--P-M---4-MKKKuKK--R-M---S-M---j1TR 96 
Days 
550 a 
450 » , 
350 ?' 
250 iJ ;::r 
150 
f: 50 
.c: 
6 a 5 
," 4 (1) A <U'1 
3 (1) 0 _0) 
-iJ 2 cStii' 
-en 1 3 3 
0 -I» 
Fig. 1. Clinical course of the combined bone marrow-liver allograft recipient (AST = aspartate aminotransferase; AL T = 
alanine aminotransferase). 
(Fig. 2a), compatible with Grade 3 acute GVHD ac-
cording to the criteria of Lerner et al. (13). The biopsy 
on POD 32 showed similar changes with continued 
damage to keratinocytes and adnexal cells (Fig. 2b) and 
a significantly more conspicuous inflammatory infil-
trate of the upper dermis than previously. Immunoper-
oxidase stains showed the cells to be T-lymphocytes of 
donor origin. Stains for Epstein-Barr virus were neg-
ative. Grossly, the skin involvement spread to approx-
imately 80070 of the body surface, including the palms, 
soles, and face. Its progress was not altered by increases 
or decreases of FK 506 or prednisone. Bouts of eosin-
ophilia (2,040/mm 3 ) and diarrhea were recorded. On 
the 42nd and 43rd POD posttransplantation, 1.23 x 
108 and 1.6 x 108 autologous BMC/kg were infused. 
The skin rash began to dramatically improve 1 wk af-
ter the autologous cell infusion and had largely re-
solved after 2 wk. At skin biopsy, four days after the 
autologous marrow infusion (POD 47), the donor cell 
infiltrate was less. Focal exocytosis of mononuclear 
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Fig. 2. (a) Skin biopsy obtained on POD 21. A mononuclear infiltrate of the superficial dermis and epidermis is associated 
with spongiosis, acantholysis and an area of confluent keratinocyte necrosis. Disruption of the dermal-epidermal junction is 
also apparent (x250). (b) Skin biopsy on postoperative day (POD) 32 showing an area of dense monoculear inflammation 
(lower left corner) with involvement and single cell necrosis of hair follicle (upper right corner). 
cells was found in association with ballooning of ba-
sal cells and aggregates of necrotic keratinocytes in the 
upper layers of the epidermis (Fig. 2c). Seven days af-
ter this (POD 54), skin biopsies had less evidence of 
acute GVHD ranging from Grade 0 to 2 (Fig. 2d). By 
this time, the rash caused by GVHD had largely re-
solved. No additional biopsies were obtained. 
The patient, who had been seriously ill, was restored 
to a sense of well being and was discharged. How-
ever, on October 13 (90 POD), he was readmitted 
with jaundice. A needle biopsy of the liver was diag-
nosed as acute viral hepatitis. Because of the additional 
diagnosis of partial biliary obstruction from ampullary 
dysfunction, the biliary reconstruction of choledocho-
dochostomy was converted to a Roux-y-choledocho-
jejunostomy on October 22, 1992. Another liver biopsy 
was obtained intraoperatively with which the diagno-
sis of C-virus hepatitis (HCV) was confirmed by iden-
tification of viral RNA using the polymerase chain 
reaction (PCR). A recipient lymph node and a segment 
of bowel excised for the biliary reconstruction were 
taken for immunocytochemical staining and histopath-
ologic staining. After immunocytochemical staining, 
both the intraabdominallymph node and segment of 
jejunum contained sparsely distributed donor cells. 
This degree of chimerism has been associated with 
graft acceptance and donor specific nonreactivity (15). 
For the 1.5 mo before as well as after the biliary re-
construction, minimum immunosuppression was given 
with 1 mg FK 506, every other day and 5 mg/day pred-
nisone. Alpha-interferon therapy was started on Oc-
tober 27. The patient was discharged on November 20. 
On February 24,1993, when the bilirubin was 1.2 mgOJo, 
immunosuppression with FK 506 was discontinued 
with continuation of 2.5 mg prednisone. On May 4, 
1993, he was admitted with a bilirubin of l.9 mgOJo 
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Fig. 2(c). Inflammation and epidermal damage is still present in the biopsy on postoperative day (POD) 47 (four days after 
autologous bone marrow infusion) (x250). 
which rose over the next 13 days to 9.7 mgmOJo. Re-
transplantation was performed on May 17, 1993, but 
the patient died 4 rna later after repeated intraabdom-
inal and systemic infections. Histopathologically, the 
primary allograft had findings of hepatitis but there 
also was evidence of rejection with obliterative arteri-
apathy and diffuse small duct loss. 
Flow cytometry (FACS II, Becton Dickinson & Co., 
Mountain View, CA) was used to determine the relative 
percentages of PBL bearing HLA Class I specific for 
the donor or recipient. Blood was collected and RBC 
were ACK-Iysed. The remaining cells were stained with 
anti-HLA Class I monoclonal antibodies (roAbs) (gen-
erously provided by Dr. Paul Terasaki) for 30 min at 
4°C and counterstained with sandwich when required. 
Donor cells were detected in the peripheral blood from 
the time of the first analysis, 11 days following liver 
transplantation. These accounted for 22-3411,70 of the 
total cell number out to POD 43 (Fig. 1), but then dra-
matically decreased following the autologous bone 
marrow infusion, to 3% at 96 days following trans-
plantation. On POD 227, cytospin examination of a 
buffy coat preparation stained with donor MHC reac-
tive monoclonal antibodies showed < 1 % donor cells. 
The cytospin during the week before retransplantation 
was negative for donor cells. 
Donor specific proliferation was assessed in MLR 
pretransplant and monthly intervals postoperatively 
for 8 mo. Before surgery, the recipient's lymphocytes 
exhibited significant proliferative responses to both 
donor and third party HLA unrelated stimulators (Ta-
ble 1). For the first month postoperatively, the patient's 
PBL showed no response to either donor or third 
party. However, the PBL blood sample from day 32 
at the time of florid GVHD was stimulated by the 
stored autologous pre-transplant PBL (3,946 cpm vs. 
269 cpm background). Three days after infusion on 
POD 42-43 of the autologous marrow, the patient's 
PBL showed highly significant spontaneous prolifer-
POD 
Table 1. MLR Responses of Peripheral Blood 
Lymphocytes from Combined Liver-Bone 
Marrow Transplant Recipient 
Proliferative Responses (CPM) 
Backg. Recipient* Donor* T.P.* 
Pre-Tx 
32 
302 
269 
32,178 
1,915 
1,890 
204 
167 
3,946 
28,058 
15,543 
173 
37,217 
27,212 
42,665 
10,842 
205 
41,024 
11,387 
24,362 
46 
62 
97 
108 
223 
227 
305 
975 
729 
3045 
2,415 
813 
225 
431 
448 
666 
*Stimulator cells were irradiated 2000R. 
8,006 
3,994 
8,656 
10,704 
5,775 
12,982 
17,723 
13,730 
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Fig. 2(d). Biopsy on postoperative (POD) 54 from the 
resolving area of rash shows only a modest mononuclear in-
filtrate associated with isolated necrotic keratinocytes. 
Changes of acute GVHD ranged from 0 to 2 in the four sam-
ples taken at this time (x250). 
ation (Table 1) which was not markedly altered by the 
addition of stored autologous, donor, or recipient 
cells. However, by POD 62, (20 days after autologous 
bone marrow infusion) spontaneous proliferation had 
died down and MLR responses to donor and third 
party were restored. For the next 2 mo, the patient's 
proliferative response to donor pretransplant lympho-
cytes was higher than that to third party. By 7 mo post-
surgery, the MLR response to the donor had dropped 
to only 250/0 of the response to third party. However, 
by 10 mo, 6 wk before retransplantation, antidonor 
party responses had recovered and were similar to 
those before the primary transplantation. 
Significant donor-specific CML activity was ob-
served with the blood sample on POD 62, 20 days fol-
lowing autologous bone-marrow infusion (Fig. 3). 
Even at a low effector:target ratio (10: 1), recipient lym-
phocytes exhibited 20% donor specific CML activity 
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Fig. 3. Donor-specific cytotoxic activity of the combined 
bone marrow-liver allograft recipient postoperative day 
(POD). 
with no CML reactivity generated towards third party 
stimulator cells then or later. This donor-specific CML 
response was not evoked by the donor cells in a sub-
sequent sample on day 97 at which time a significant 
proliferative response in MLR still was present. 
DISCUSSION 
These results indicate that stored autologous bone 
marrow could constitute a safety net for GVHD in 
splanchnic organ recipients or in clinical trials of bone 
marrow transplantation that are designed to induce do-
nor specific unresponsiveness for whole organ or non-
hematolymphopoietic (i. e., islet) cell transplantation. 
Neither temporary reduction of immunosuppression 
nor augmentation of treatment affected the GVHD. 
After the autologous cell infusion, the skin biopsy was 
better within 4 days, and dramatic clinical improve-
ment was evident by the end of the week. 
Ten days before the bone marrow infusion, the 
MLR showed no response against donor or third party, 
indicating the profoundly immunocompromised status 
of the recipient. This could explain why the recipient 
peripheral leukocytes were ineffective in control of the 
GVHD, despite their quantitative advantage relative to 
the infused bone marrow cells which had been removed 
and cryopreserved preoperatively, before the patient 
underwent radiation treatment or was exposed to phar-
macologic immunosuppression. The infused autologous 
cells retained their ability to reverse the GVHD, and 
ultimately, the alloreactivity of the circulating recipient 
cells to those of the donor was restored to levels that 
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were even higher than those observed pre-transplanta-
tion. Eventually, the recipient whose immunosup-
pression had been stopped regained enough immune 
competence to reject the graft which also was afflicted 
with severe HeV. The autologous cell treatment could 
be considered analogous to the "tolerance breaking" 
experiments described by Billingham, Brent, and Me-
dawar (16). 
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